NICE will develop standards for using real world data as part of a new five-year strategic plan that the UK health technology assessment body hopes will make it a leader in the use of research and data.
Driven by its work to develop guidelines on COVID-19 during the pandemic, NICE, the health technology appraisal institute for England and Wales, has published a five-year strategic plan that it says will enable it to produce “dynamic and living” guidelines, make it more collaborative, and put itself at the forefront of using real world data in decision making.
“The COVID-19 pandemic has reaffirmed the need to place science and evidence at the heart of health and care decision...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
